-
Patent Agency Ranking
公开(公告)号：US20070172454A1
公开(公告)日：2007-07-26
申请号：US11622284
申请日：2007-01-11
Applicant: Nicole Deglon , Patrick Aebischer , Jean-Charles Bensadoun
Inventor： Nicole Deglon , Patrick Aebischer , Jean-Charles Bensadoun
IPC: A61K48/00 , A61K38/20 , C12N15/867
CPC classification number: A61K38/204 , A61K48/00
Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
Abstract translation: 本发明涉及IL-6R / IL-6嵌合体，突变蛋白，同种型，融合蛋白，功能衍生物，活性级分或环状置换衍生物或其盐在制备用于治疗和/ 或预防亨廷顿氏病。
-
公开(公告)号：US08329654B2
公开(公告)日：2012-12-11
申请号：US12717305
申请日：2010-03-04
Applicant: Nicole Deglon , Patrick Aebischer , Jean-Charles Bensadoun
Inventor： Nicole Deglon , Patrick Aebischer , Jean-Charles Bensadoun
CPC classification number: A61K38/204 , A61K48/00
Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
Abstract translation: 本发明涉及IL-6R / IL-6嵌合体，突变蛋白，同种型，融合蛋白，功能衍生物，活性级分或环状置换衍生物或其盐在制备用于治疗和/ 或预防亨廷顿氏病。
-
公开(公告)号：US5952226A
公开(公告)日：1999-09-14
申请号：US853236
申请日：1997-05-09
Applicant: Patrick Aebischer , Nicole Deglon , Etienne Regulier , Christopher Rinsch
Inventor： Patrick Aebischer , Nicole Deglon , Etienne Regulier , Christopher Rinsch
CPC classification number: A61K9/0092 , A61K38/1816 , A61K48/00 , A61K9/0024 , A61K2035/126
Abstract: A device and method for delivery of EPO to a patient using an implanted device that continuously releases EPO.
Abstract translation: 使用连续释放EPO的植入装置将EPO递送给患者的装置和方法。
-
4.发明授权Reversible siRNA-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease 有权突变型和内源性野生型亨廷顿病基因的可逆siRNA基沉默及其在亨廷顿病中的应用公开(公告)号：US08217018B2
公开(公告)日：2012-07-10
申请号：US12665137
申请日：2008-06-18
Applicant: Valérie Perrin , Nicole Deglon
Inventor： Valérie Perrin , Nicole Deglon
CPC classification number: C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
Abstract: Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models.
Abstract translation: 分离的双链短干扰核酸分子，其抑制表达两种所述亨廷顿蛋白基因的非人哺乳动物细胞内源性野生型和外源性人类突变型亨廷顿基因的表达，以及它们在亨廷顿舞蹈病中的应用 在啮齿动物模型中研究亨廷顿病。
-
5.发明申请Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease 有权突变型和内源性野生型亨廷顿蛋白基因的可逆siRNA基沉默及其在亨廷顿氏病治疗中的应用公开(公告)号：US20100299768A1
公开(公告)日：2010-11-25
申请号：US12665137
申请日：2008-06-18
Applicant: Valerie Perrin , Nicole Deglon
Inventor： Valerie Perrin , Nicole Deglon
IPC: A01K67/00 , C07H21/04 , C12N15/63 , C12N5/10 , A61K31/7088
CPC classification number: C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
Abstract: Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models.
Abstract translation: 分离的双链短干扰核酸分子，其抑制表达两种所述亨廷顿蛋白基因的非人哺乳动物细胞内源性野生型和外源性人类突变型亨廷顿基因的表达，以及它们在亨廷顿病中的应用 在啮齿动物模型中研究亨廷顿病。
-
-
-
-
Search Results
5
records
(took 0.019 seconds)
